

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ANCLIFF, Rachael *et al.*
Serial No.: 10/531,758
Filing Date: April 14, 2005

Group Art Unit: 1624
Examiner: COLEMAN, Brenda Libby

Confirmation No.: 5647
Attorney Docket No.: P33126USw

Title: *Substituted Piperazines (1,4) Diazepines, and 2,5-Diazabicyclo (2.2.1) Heptanes as Histamine H1 and/or H3 Antagonists or Histamine H3 Reverse Antagonists*

MAIL STOP ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION TO CORRECT INVENTORSHIP UNDER 37 CFR §1.48(b)

This Petition is filed under 37 CFR §1.48(b) with the payment of the Issue Fee. In this application, fewer inventors should be listed due to amendment or cancellation of claims. The correct inventors were named in this non-provisional application as filed. Prosecution of this application resulted in the amendment or cancellation of the claims, such that fewer than all of the currently-named inventors are the actual inventors of the invention being claimed.

Applicants hereby request that the inventorship be amended as follows:

As originally-filed, the following individuals were listed as inventors:

ANCLIFF, Rachael
ELDRED, Colin David
FOGDEN, Yvonne C.
HANCOCK, Ashley Paul
HEIGHTMAN, Thomas Daniel
HOBBS, Heather
HODGSON, Simon Teanby
LINDON, Matthew J.
WILSON, David Matthew

Please **delete** the following individuals from the list of inventors, as these individuals' contributions are no longer being claimed in this application:

ANCLIFF, Rachael
ELDRED, Colin David
FOGDEN, Yvonne C.
HANCOCK, Ashley Paul
HOBBS, Heather

As such, the inventors of the claimed subject matter are the following:

HEIGHTMAN, Thomas Daniel
HODGSON, Simon Teanby
LINDON, Matthew J.
WILSON, David Matthew

The Commissioner is hereby authorized to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR §1.16 or §1.17, including the processing fee set forth in §1.17(i), and any necessary extension of time fees, to Deposit Account No. 07-1392.

Approval of this Petition and Amendment of the named Inventorship is respectfully requested.

Respectfully submitted,

/James P. Riek/

James P. Riek
Attorney for Applicant
Registration No. 39,009

Date: 14 September 2009
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988